Most recently, Bob served as the vice-president of corporate distribution at Biomet focusing on commercial execution strategies across the strategic business units. Prior to this role, he was senior vice-president of sales for Biomet’s BTBS (EBI) division involved with spine, trauma, osteo-biologics and sports medicine products. Bob also served as area vice-president for the Northeast and Mid-Atlantic regions in the joint reconstruction franchise.

Before Biomet, Bob was the vice-president of sales & marketing at Biosphere Medical, an early stage company, where he helped establish the use of microsphere technology with interventional radiologists and neuroradiologists. At Johnson & Johnson, where he began his career, Bob held various senior executive roles including vice-president of group contracting and vice-president of sales for the orthopedic business (now DePuy).

David Cerveny brings more than a decade of experience in medical devices and intellectual property to his role as vice president of intellectual property & general counsel for ConforMIS. David will be assuming the responsibility of managing ConforMIS’ legal affairs as well as expanding the company’s intellectual property portfolio and patent strategy.

Prior to joining ConforMIS, David was the chief intellectual property counsel for Palomar Medical Technologies, where he managed a patent portfolio widely regarded as the strongest in that industry. Before Palomar, David was a senior attorney in the intellectual property practice at Proskauer Rose LLP and a partner at Wilmer Cutler Pickering Hale and Dorr LLP. He earned a J.D. from Boston College Law School, and was twice named a Massachusetts Super Lawyers rising star.

The recent additions to the executive management team are designed to support ConforMIS’ continued momentum and growth as it enters its next stage of commercialization. “With the introduction of the iUni® unicompartmental and iDuo® bicompartmental knee resurfacing implants, we have seen a strong and accelerating interest in our technologies with over 250 active surgeons,” said Philipp Lang, chief executive officer of ConforMIS “Bob Phelps and David Cerveny enable us to strengthen our unique position within the orthopedic industry as the only company offering an entirely patient-specific approach to the knee replacement market.”